{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027356","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-08-12T20:52:25+00:00","discovered_at":"2026-08-12T20:53:03.326862+00:00","generated_at":"2026-08-12T20:53:08.873150+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Reviva Q2 net loss narrows to $2.4M; cash $19.9M; brilaroxazine patent extension pursued","bullets":["Net loss $2.4M ($0.19/share) for Q2 2026 vs $6.1M ($2.40/share) year ago; per-share reflects 1:20 reverse split.","Cash and equivalents $19.9M at June 30, 2026 vs $14.4M at Dec 31, 2025.","Filed US composition-of-matter patent for new brilaroxazine form to extend exclusivity through 2046.","FDA feedback on using new formulation in RECOVER-2 trial and NDA expected Q4 2026; bioequivalence study planned Q4 2026.","Patient enrollment in RECOVER-2 Phase 3 trial expected 1H 2027, subject to additional financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027356","json":"https://secwatch.observer/filing/0001437749-26-027356.json","markdown":"https://secwatch.observer/filing/0001437749-26-027356.md","text":"https://secwatch.observer/filing/0001437749-26-027356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/0001437749-26-027356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/rvph20260729_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:53:08.873150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}